DekaBank Deutsche Girozentrale
SPRO icon

DekaBank Deutsche Girozentrale’s Spero Therapeutics SPRO Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,500
Closed -$114K – 1415
2021
Q1 		$114K Hold
8,500
– – ﹤0.01% 1273
2020
Q4 		$171K Buy
+8,500
New +$133K ﹤0.01% 1204

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

DekaBank Deutsche Girozentrale's SPRO Position: Q2 2021 in Review

DekaBank Deutsche Girozentrale sold out of Spero Therapeutics (SPRO) in Q2 2021, closing a stake of 8,500 shares — an estimated $114K sold.

DekaBank Deutsche Girozentrale first reported a position in SPRO in Q4 2020 and held it in 2 quarters. The position peaked at $171K in Q4 2020. 88 funds tracked by Wall St. Rank hold SPRO as of Q2 2021.

  • DekaBank Deutsche Girozentrale reported no remaining Spero Therapeutics position as of Q2 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 8,500 Spero Therapeutics shares in Q2 2021, an estimated $114K.
  • DekaBank Deutsche Girozentrale first reported a position in Spero Therapeutics in Q4 2020 and held it in 2 quarters.
  • DekaBank Deutsche Girozentrale's Spero Therapeutics position peaked at $171K in Q4 2020.
  • 88 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2021, filed 5 Aug 2021.